Evotec (NASDAQ:EVO) Sees Large Volume Increase – Here’s Why

Evotec AG (NASDAQ:EVO) shares saw strong trading volume on Tuesday . 205,273 shares changed hands during trading, an increase of 51% from the previous session’s volume of 136,383 shares.The stock last traded at $2.5450 and had previously closed at $2.62.

Wall Street Analysts Forecast Growth

EVO has been the subject of a number of recent research reports. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Berenberg Bank initiated coverage on Evotec in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.00.

Evotec Price Performance

The business has a 50 day moving average of $3.07 and a 200 day moving average of $3.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03.

Institutional Trading of Evotec

A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its position in Evotec by 25.7% in the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after acquiring an additional 367,545 shares during the period. DCF Advisers LLC grew its position in Evotec by 7.6% in the third quarter. DCF Advisers LLC now owns 1,198,993 shares of the company’s stock valued at $4,352,000 after acquiring an additional 84,500 shares during the period. ABC Arbitrage SA grew its position in Evotec by 319.7% in the fourth quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock valued at $1,707,000 after acquiring an additional 422,230 shares during the period. Pitcairn Co. bought a new stake in Evotec in the second quarter valued at $1,097,000. Finally, Jane Street Group LLC bought a new stake in Evotec in the fourth quarter valued at $565,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.